KDR and neoplasm: After almost a decade of plateau in survival in metastatic GC (mGC), the advent of vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors such as ramucirumab [5,6] and apatinib [7], as well as the innovative oral cytotoxic trifluridine-tipiracil [8] and, especially in particular subgroups of patients (i.e., programmed death [PD] ligand 1 [PD-L1] positive, microsatellite instability [MSI]-high, Epstein–Barr virus [EBV], positive or high tumor mutational burden [TMB]), immune checkpoint inhibitors (ICIs) [9,10] led to progressive incremental survival advantages.